C1

Consun Pharmaceutical Group LtdFRA Consun Pharmaceutical Stock Report

Last reporting period 31 Dec, 2023

Updated 12 Nov, 2024

Last price

Market cap $B

0.7

Micro

Exchange

XFRA - Deutsche Boerse AG

C1P.F Stock Analysis

C1

Uncovered

Consun Pharmaceutical Group Ltd is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

126/100

High score

Market cap $B

0.7

Dividend yield

18.52 %

Shares outstanding

788.49 B

Consun Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The pharmaceutical products of the Company include kidney medicines, contrast medium and others. The Company’s subsidiaries include Brilliant Reach Group Limited, Century International Develop Limited and Grand Reach Company Limited. Through its subsidiaries, the Company is also engaged in the research and development of pharmaceutical products.

View Section: Eyestock Rating